Public formulary and program coverage makes AJOVY®
accessible to more migraine patients across Canada
MONTRÉAL, Mar. 2, 2022 /CNW/
- Teva Canada Limited, a subsidiary of Teva Pharmaceutical
Industries Ltd., welcomes the recently announced public formulary
coverage for AJOVY® (fremanezumab) by Alberta, Saskatchewan, Québec, Veteran Affairs Canada
(VAC) and the Non-Insured Health Benefits (NIHB)
Program.1,2,3,4 AJOVY® is a subcutaneous
injection for the preventive treatment of migraine in adults who
have at least four migraine days per month.5 Public
formulary coverage will help make AJOVY® accessible to
more patients across Canada. Teva
Canada hopes that other public drug plans across Canada will soon make AJOVY®
available to the eligible patients in their jurisdictions.
Public formulary and program coverage makes
AJOVY® (fremanezumab) accessible to more migraine patients across
Canada
"Public coverage opens so many doors for those living with
migraine to improve their quality of life; coverage for
AJOVY® is an enormous step in the right direction," said
Louise Houle, Executive Director of
Migraine Québec. "As an advocate for people with migraine and as a
person with chronic migraine, I'm gratified to see this disabling
neurological disease get so much attention and to see more access
to new treatment options."
"Migraine impacts every aspect of a person's life and finding
the right treatment may require many trials," said Dr. Elizabeth Leroux, a researcher and neurologist
with an expertise in migraine and headache management, and
President of the Canadian Headache Society. "As a physician, I want
all options to be available to my patients and public coverage is
critical for many people to access recent treatments. Provincial
coverage for AJOVY® is great news."
AJOVY® is available in two formats and two dosing
regimens5, giving prescribers and patients treatment
flexibility to help suit their needs. AJOVY® is
supported by the AJOVY® Teva Support
Solutions® (AJOVY® TSS) Patient Support
Program.
"At Teva Canada, we welcome these new provincial formulary
listings that afford greater access to AJOVY® and its
flexible treatment choices for migraine patients with
individualized needs," said Christine
Poulin, General Manager at Teva Canada. "These formulary
listings are based on established evidence-based drug funding
review processes, and we are pleased for patients and prescribers
that AJOVY® met the criteria for listing."
About Migraine
Migraine is a disabling chronic neurological disease that causes
head pain so severe that sufferers often cannot function during an
attack. Migraine reduces quality of life and disrupts migraineurs'
ability to perform daily activities.6,7 It is among the
top 10 causes of disability worldwide and the seventh cause of
years of life lost to disability.8,9,10 In Canada, migraine is most common in women and
most common between the ages of 30 and 49.11 Migraine
therefore reduces patients' quality of life, ability to work, and
overall productivity right at the prime of their life. While acute
treatment modalities are used to treat migraine attacks when they
occur, they do not prevent them. Novel treatments like
AJOVY® were specifically designed to actually prevent
migraine from occurring.
About AJOVY®
AJOVY®
(fremanezumab) is indicated for the preventive treatment of
migraine in adults who have at least four migraine days per month.
AJOVY® is available as a 225 mg/1.5 mL single-dose
injection in an autoinjector or prefilled syringe with two dosing
options: 225 mg monthly, administered as one subcutaneous
injection; or 675 mg every three months (quarterly), administered
as three subcutaneous injections. AJOVY® is intended for
patient self-administration after the patient or their caretaker
has been trained to administer the product. AJOVY®
patients and prescribers are supported by the AJOVY®
Teva Support Solutions® Patient Support
Program.5
About Teva Canada
Teva Canada, headquartered in
Toronto, has provided affordable
healthcare solutions to Canadians for over 50 years, building their
trust one prescription at a time with now more than
290,00012 prescriptions filled each day with our
products, representing 1 of every 5 generic prescriptions in
Canada.13 Originally
Novopharm Limited, Teva Canada specializes in the development,
production, and marketing of high-quality generic prescription
pharmaceuticals and, through our branded division, focuses on a
diverse line of specialty and biopharmaceutical products in a
variety of therapeutic areas such as central nervous system (CNS),
respiratory, oncology and rheumatology. Teva Canada's commitment to
helping improve the lives of Canadians also extends to the Teva
Caregiver program – providing tools and resources for Canadians
navigating the care journey. Teva Canada employs more than 900
professionals, had sales of nearly $1.2
billion14 in 2021, and markets more than
32015 products in over 935 SKUs15 in
Canada. We are a proud subsidiary
of Teva Pharmaceutical Industries Ltd. Learn more at
www.tevacanada.com.
About Teva Pharmaceuticals Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been
developing and producing medicines to improve people's lives for
more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
_________________________
|
1.
|
Régie de l'assurance
maladie du Québec. List of Medications. Available from:
https://www.ramq.gouv.qc.ca/en/about-us/list-medications
|
2.
|
Saskatchewan Drug Plan
information available from:
https://formulary.drugplan.ehealthsask.ca/SearchFormulary/
|
3.
|
Alberta Health. Drug
Benefit List. Available from:
https://idbl.ab.bluecross.ca/idbl/load.do
|
4.
|
Non-Insured Health
Benefits (NIHB) Program list. Available from:
https://nihb-ssna.express-scripts.ca/en/0205140506092019/16/160407
|
5.
|
AJOVY® Product
Monograph. Teva Canada Limited, Montréal, Quebec – January 19,
2022.
|
6.
|
Buse DC, Rupnow MF,
Lipton RB. Assessing and managing all aspects of migraine: migraine
attacks, migraine-related functional impairment, common
comorbidities, and quality of life. Mayo Clin Proc.
2009;84:422–435. doi: 10.1016/S0025-6196(11)60561-2.
|
7.
|
Lipton RB, Liberman JN,
Kolodner KB, et al. Migraine headache disability and health-related
quality-of-life: a population-based case-control study from
England. Cephalalgia. 2003;23:441–450. doi:
10.1046/j.1468-2982.2003.00546.x.
|
8.
|
Steiner TJ, Stovner LJ,
Birbeck GL. Migraine: the seventh disabler. J Headache Pain.
2013;14:1. doi: 10.1186/1129-2377-14-1
|
9.
|
Global Burden of
Disease Study Collaborators. Global, regional, and national
incidence, prevalence, and years lived with disability for 301
acute and chronic diseases and injuries in 188 countries,
1990–2013: a systematic analysis for the Global Burden of Disease
Study 2013. Lancet. 2015;386:743– 800. doi:
10.1016/S0140-6736(15)60692-4.
|
10.
|
Institute for Health
Metrics and Evaluation. Global burden of disease visualization
tools. Available from:
http://vizhub.healthdata.org/gbd-compare/ Accessed January
2016.
|
11.
|
Ramage-Morin PL,
Gilmour H. Prevalence of migraine in the Canadian household
population. Health Rep. 2014;25(6):10–16.
|
12.
|
Source: IQVIA CDH
Compuscript TRx MAT Dec 2021.
|
13.
|
Source: IQVIA
Compuscript Trx MAT 2021.12.
|
14.
|
Source: IQVIA CDH &
Compuscript MAT Dec 2021.
|
15.
|
Source: Teva Price list
January 17, 2022.
|
![Teva Canada logo (CNW Group/Teva Canada) Teva Canada logo (CNW Group/Teva Canada)](https://mma.prnewswire.com/media/1755034/Teva___cmyk_uncoated_02.jpg)
SOURCE Teva Canada